InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Publishes Preclinical Data Showing Improved Insulin Sensitivity in Type 2 Diabetes Model
Telomir Pharmaceuticals (NASDAQ: TELO) announced the peer-reviewed publication of preclinical data in Biomedicine & Pharmacotherapy demonstrating that its lead candidate, Telomir-Zn, restored insulin sensitivity and improved glucose homeostasis in a diet-induced zebrafish model of Type 2 diabetes. According to the study, treatment produced dose-dependent reductions in fasting blood glucose and insulin levels, improved glucose tolerance, and significantly lowered HOMA-IR scores, a widely used measure of insulin resistance. The company said…